176 related articles for article (PubMed ID: 36129129)
1. Leveraging patient-centric sampling for clinical drug development and decentralized clinical trials: Promise to reality.
Maass KF; Barfield MD; Ito M; James CA; Kavetska O; Kozinn M; Kumar P; Lepak M; Leuthold LA; Li W; Mikhailov D; Patel S; Perez NL; Jackson Rudd D; Vakkalagadda B; Williams TM; Zha J; Zhang X; Anderson MD
Clin Transl Sci; 2022 Dec; 15(12):2785-2795. PubMed ID: 36129129
[TBL] [Abstract][Full Text] [Related]
2. Enhancing drug development and clinical studies with patient-centric sampling using microsampling techniques: Opportunities, challenges, and insights into liquid chromatography-mass spectrometry strategies.
Chen Z; Goudarzi CC; Sikorski TW; Weng N
J Mass Spectrom; 2024 May; 59(5):e5023. PubMed ID: 38624283
[TBL] [Abstract][Full Text] [Related]
3. Digitally Enabled, Patient-Centric Clinical Trials: Shifting the Drug Development Paradigm.
Dockendorf MF; Hansen BJ; Bateman KP; Moyer M; Shah JK; Shipley LA
Clin Transl Sci; 2021 Mar; 14(2):445-459. PubMed ID: 33048475
[TBL] [Abstract][Full Text] [Related]
4. Harnessing the Potential of Emerging Digital Health and Biological Sampling Technologies for Clinical Drug Development: Promise to Reality.
Kothare PA; Jadhav PR; Gupta P; Harrelson JC; Dickmann L
Clin Pharmacol Ther; 2018 Dec; 104(6):1125-1135. PubMed ID: 29696625
[TBL] [Abstract][Full Text] [Related]
5. Land O'Lakes Workshop on Microsampling: Enabling Broader Adoption.
Wickremsinhe ER; Ji QC; Gleason CR; Anderson M; Booth BP
AAPS J; 2020 Oct; 22(6):135. PubMed ID: 33098040
[TBL] [Abstract][Full Text] [Related]
6. The development of patient-centric sampling as an enabling technology for clinical trials.
P Bateman K
Bioanalysis; 2020 Jul; 12(13):971-976. PubMed ID: 32628048
[TBL] [Abstract][Full Text] [Related]
7. Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report.
Abend A; Heimbach T; Cohen M; Kesisoglou F; Pepin X; Suarez-Sharp S
AAPS J; 2018 Apr; 20(3):60. PubMed ID: 29633092
[TBL] [Abstract][Full Text] [Related]
8. The Next Horizon of Drug Development: External Control Arms and Innovative Tools to Enrich Clinical Trial Data.
Zou KH; Vigna C; Talwai A; Jain R; Galaznik A; Berger ML; Li JZ
Ther Innov Regul Sci; 2024 May; 58(3):443-455. PubMed ID: 38528279
[TBL] [Abstract][Full Text] [Related]
9. The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development.
Iersel TV; Courville J; Doorne CV; Koster RA; Fawcett C
Curr Rev Clin Exp Pharmacol; 2022; 17(1):8-17. PubMed ID: 34455946
[TBL] [Abstract][Full Text] [Related]
10. Adoption of Decentralization: Are Our Perceptions Holding Us Back?
Kehoe L; Calvert SB; Hallinan Z; Hanger M
Ther Innov Regul Sci; 2024 Mar; ():. PubMed ID: 38546961
[TBL] [Abstract][Full Text] [Related]
11. Rational and practical considerations to guide a target product profile for patient-centric drug product development with measurable patient outcomes - A proposed roadmap.
Stegemann S; Sheehan L; Rossi A; Barrett A; Paudel A; Crean A; Ruiz F; Bresciani M; Liu F; Shariff Z; Shine M; Schmelzer C; Pense-Lheritier AM
Eur J Pharm Biopharm; 2022 Aug; 177():81-88. PubMed ID: 35718077
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Financial Value of Decentralized Clinical Trials.
DiMasi JA; Smith Z; Oakley-Girvan I; Mackinnon A; Costello M; Tenaerts P; Getz KA
Ther Innov Regul Sci; 2023 Mar; 57(2):209-219. PubMed ID: 36104654
[TBL] [Abstract][Full Text] [Related]
13. Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group.
Li W; Vazvaei-Smith F; Dear G; Boer J; Cuyckens F; Fraier D; Liang Y; Lu D; Mangus H; Moliner P; Pedersen ML; Romeo AA; Spracklin DK; Wagner DS; Winter S; Xu XS
Clin Pharmacol Ther; 2024 May; 115(5):939-953. PubMed ID: 38073140
[TBL] [Abstract][Full Text] [Related]
14. Gathering Structured Patient Insight to Drive the PRO Strategy in COPD: Patient-Centric Drug Development from Theory to Practice.
Patalano F; Gutzwiller FS; Shah B; Kumari C; Cook NS
Adv Ther; 2020 Jan; 37(1):17-26. PubMed ID: 31707715
[TBL] [Abstract][Full Text] [Related]
15. Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019.
Tan DCT; Khong YM; Mount S; Galella E; Mitra B; Charlton S; Kuhli M; Ternik R; Walsh J; Rajapakshe A; Thompson K; Mehrotra S; Santangelo M; Liu J; Dixit T; Schaufelberger D; Jamzad S; Klein S; Hoag SW; Wang J; Fletcher EP; Khurana M; Alexander J; Radden E; Sood R; Selen A
Eur J Pharm Biopharm; 2021 Jul; 164():54-65. PubMed ID: 33878432
[TBL] [Abstract][Full Text] [Related]
16. Giving patients choices: AstraZeneca's evolving approach to patient-centric sampling.
Bailey C; Arfvidsson C; Woodford L; Kock M
Bioanalysis; 2020 Jul; 12(13):957-970. PubMed ID: 32716627
[TBL] [Abstract][Full Text] [Related]
17. Patient-centric drug product development: Acceptability across patient populations - Science and evidence.
Stegemann S; Klingmann V; Reidemeister S; Breitkreutz J
Eur J Pharm Biopharm; 2023 Jul; 188():1-5. PubMed ID: 37164232
[TBL] [Abstract][Full Text] [Related]
18. Stakeholder Perspectives on Barriers and Facilitators for the Adoption of Virtual Clinical Trials: Qualitative Study.
Coert RMH; Timmis JK; Boorsma A; Pasman WJ
J Med Internet Res; 2021 Jul; 23(7):e26813. PubMed ID: 34255673
[TBL] [Abstract][Full Text] [Related]
19. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
20. Microsampling: considerations for its use in pharmaceutical drug discovery and development.
Spooner N; Anderson KD; Siple J; Wickremsinhe ER; Xu Y; Lee M
Bioanalysis; 2019 May; 11(10):1015-1038. PubMed ID: 31218897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
